Glucagon, Glicentin, and Related Peptides

Moody, A. J.; Thim, Lars

doi:10.1007/978-3-642-68866-9_7

Cited by 14 publications

(1 citation statement)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same proportion of these two peptides in the central nervous system and the gut indicates that a similar posttranslational processing exists in these rat tissues, another example of the brain-gut axis. (Endocrinology 123: [2782][2783][2784][2785][2786][2787]1988) G UT GLUCAGON-like immunoreactivity (gut GLI), also called enteroglucagon (1,2), is a family of peptides from the gastrointestinal tract that bind to antibodies directed toward the central region of glucagon, but not to antibodies raised against the C-terminal region of the molecule. Oxyntomodulin (OXM) (3,4) and glicentin (5) have been demonstrated to be the main gut GLI components in human and rat small intestine (6,7) and in rat plasma (6).…”

mentioning

confidence: 99%

Oxyntomodulin and Glicentin: Brain-Gut Peptides in the Rat*

1988

View full text Add to dashboard Cite

Glucagon-like materials and glucagon have been identified by immunoassay and immunocytochemistry in the mammalian central nervous system. However, the molecular forms relevant to brain glucagon-like immunoreactivity (GLI) have not been precisely defined. In the rat small intestine, more than 90% of GLI is constituted by two peptides: oxyntomodulin (OXM) and glicentin. This work was initiated to characterize and determine the concentrations of these two peptides and glucagon in the rat central nervous system and to compare their relative proportions with those found in the gut. Different regions from the adult rat brain were analyzed by HPLC in association with RIA, using a central glucagon antiserum and an antibody directed toward the C-terminal end of OXM and glicentin. The elution profiles of hypothalamus extracts were constituted by two main peaks, both detected by the two antibodies used and displaying the same retention times as glicentin and OXM, respectively. A third small peak, which coeluted with glucagon, was constantly recorded with the central glucagon antiserum. The percentages of glicentin, OXM, and glucagon in 10 hypothalami were 37 +/- 1%, 55 +/- 1%, and 8 +/- 2%, respectively (n = 8). This distribution was quite similar to that in small intestinal extracts (38 +/- 1%, 59 +/- 1%, and 1.3 +/- 0.1%, respectively; n = 7); however, the peptide concentrations were almost 50-fold greater in intestine than in hypothalamus. In the medulla oblongata, the same peptide ratio was observed, with 10-fold lower concentrations compared to those in hypothalamus. In olfactory bulb, cerebellum, and cortex the concentrations were close the the detection limit, whereas they could be not detected in the pituitary. The combination of HPLC and specific RIAs allowed us to unambiguously characterize OXM and glicentin as the major components of GLI in the rat hypothalamus and medulla oblongata. The same proportion of these two peptides in the central nervous system and the gut indicates that a similar posttranslational processing exists in these rat tissues, another example of the brain-gut axis.

show abstract